We synthesized a novel synthetic chemical library and used it in a forward chemical genetics screen designed to identify small molecule inhibitors of endothelial morphogenesis. This screen resulted in the identification of structurally-related small molecules that inhibited endothelial cell proliferation, migration, the ability to form tubule-like structures in matrigel, as well as neo- angiogenesis visualized using a dorsal skin fold vascular window chamber. Biochemical analysis revealed that the novel small molecules inhibited ENOX1, a plasma membrane- associated enzyme that exhibits protein disulfide-thiol interchange activity. While ENOX activity is important for cellular proliferation, the molecular mechanisms are not well understood. shRNA-mediated inhibition of ENOX activity in HUVECs inhibited endothelial cell migration and formation of tubule-like structures in matrigel, reproducing the effects of the small molecule inhibitors. Small molecule inhibition of ENOX1 was associated with a significant increase in endothelial cell apoptosis induced by ionizing radiation. Colony formation assays demonstrated that these small molecules increased the radiation sensitivity of endothelial cells. In contrast, the radiation sensitivity of tumor epithelial cells was unaffected by the small molecules. Administration of a small molecule ENOX1 inhibitor prior to fractionated X-irradiation produced a statistically significant decrease in the number and density of CD34 expressing Lewis Lung Carcinoma (LLC) tumor-associated microvasculature. Use of LLC and human HT29 colon carcinoma tumor models demonstrated that the small molecule ENOX1 inhibitors coupled with fractionated X-irradiation produced a statistically significant increase in tumor growth delay compared to irradiation alone. No evidence of acute toxicity was observed over a 30 day interval when mice received a bolus injection of 120 mg/kg. These preliminary data support the hypothesis that ENOX1 represents a rationale molecular target for increasing the ability of ionizing radiation to control tumor growth. The short term goal of this application is to valid this hypothesis. The long term goal is to develop these small molecule inhibitors into a radiation sensitizer that exhibits clinical efficacy.

Public Health Relevance

A forward chemical genetics screen identifies small molecule inhibitors of endothelial morphogenesis. Biochemical analysis revealed that these novel small molecules inhibited the enzyme ENOX1, increased the radiation sensitivity of endothelial cells, increased radiation- mediated suppression of tumor-associated vasculature, thereby suppressing tumor growth. These preliminary data support the hypothesis that ENOX1 represents a rationale molecular target for increasing the ability of ionizing radiation to control tumor growth.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA140409-01A1
Application #
7787394
Study Section
Radiation Therapeutics and Biology Study Section (RTB)
Program Officer
Bernhard, Eric J
Project Start
2009-12-11
Project End
2014-11-30
Budget Start
2009-12-11
Budget End
2010-11-30
Support Year
1
Fiscal Year
2010
Total Cost
$358,801
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Cleyrat, Cédric; Girard, Romain; Choi, Eun H et al. (2017) Gene editing rescue of a novel MPL mutant associated with congenital amegakaryocytic thrombocytopenia. Blood Adv 1:1815-1826
Smith, Clayton A; Mont, Stacey; Traver, Geri et al. (2016) Targeting Enox1 in tumor stroma increases the efficacy of fractionated radiotherapy. Oncotarget 7:77926-77936
Mont, Stacey; Davies, Sean S; Roberts Second, L Jackson et al. (2016) Accumulation of isolevuglandin-modified protein in normal and fibrotic lung. Sci Rep 6:24919
Madadi, Nikhil R; Zong, Hongliang; Ketkar, Amit et al. (2015) Synthesis and evaluation of a series of resveratrol analogues as potent anti-cancer agents that target tubulin. Medchemcomm 6:788-794
Jang, Dae Song; Penthala, Narsimha R; Apostolov, Eugene O et al. (2015) Novel high-throughput deoxyribonuclease 1 assay. J Biomol Screen 20:202-11
Madadi, Nikhil R; Penthala, Narsimha R; Howk, Kevin et al. (2015) Synthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4. Eur J Med Chem 103:123-32
Penthala, Narsimha Reddy; Ketkar, Amit; Sekhar, Konjeti R et al. (2015) 1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1). Bioorg Med Chem 23:7226-33
Penthala, Narsimha Reddy; Zong, Hongliang; Ketkar, Amit et al. (2015) Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agents. Eur J Med Chem 92:212-20
Penthala, Narsimha Reddy; Thakkar, Shraddha; Crooks, Peter A (2015) Heteroaromatic analogs of the resveratrol analog DMU-212 as potent anti-cancer agents. Bioorg Med Chem Lett 25:2763-7
Jang, Dae Song; Penthala, Narsimha R; Apostolov, Eugene O et al. (2015) Novel cytoprotective inhibitors for apoptotic endonuclease G. DNA Cell Biol 34:92-100

Showing the most recent 10 out of 27 publications